EMGE Stock Overview
Develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Emergent Health Corp Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.001 |
| 52 Week High | US$0.0041 |
| 52 Week Low | US$0.00055 |
| Beta | 0 |
| 11 Month Change | -16.67% |
| 3 Month Change | -35.48% |
| 1 Year Change | 0% |
| 33 Year Change | -98.08% |
| 5 Year Change | -99.38% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | 0% | 15.6% | 30.7% |
Return vs Industry: EMGE underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: EMGE underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| EMGE volatility | |
|---|---|
| EMGE Average Weekly Movement | 17.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMGE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EMGE's weekly volatility has decreased from 46% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | James Zimbler | www.emergenthealthcorp.com |
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally.
Emergent Health Corp Fundamentals Summary
| EMGE fundamental statistics | |
|---|---|
| Market cap | US$426.95k |
| Earnings (TTM) | -US$288.76k |
| Revenue (TTM) | US$119.57k |
0.0x
P/S Ratio0.0x
P/E RatioIs EMGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMGE income statement (TTM) | |
|---|---|
| Revenue | US$119.57k |
| Cost of Revenue | US$40.09k |
| Gross Profit | US$79.48k |
| Other Expenses | US$368.24k |
| Earnings | -US$288.76k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EMGE perform over the long term?
See historical performance and comparison